stockrowAdagio Medical Holdings, Inc.
ADGMAdagio Medical Holdings, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $602,000.00, up 100.7% from fiscal 2023.
- Revenue
- −33.5%
- EPS
- −15.4%
- Free cash flow
- −12.9%
- Total debt
- +46.6%
Quarter to June 2026, against a year earlier
Follow ADGM
Alert me
Adagio Medical Holdings, Inc. (ADGM) EV/Sales
As of 6 November 2026, Adagio Medical Holdings, Inc. (ADGM) trades at a EV/Sales of 30.6×. Over the past ten years it has ranged from 0.0× (June 2024) to 87.7× (October 2025); the current reading is higher than 69% of that period. That is above the Medical Devices industry median of 2.8× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 19.7× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 19.7× | (45.62%) |
| Sep 2024 | 36.2× | 133.39% |
| Jun 2024 | 15.5× | — |
| Mar 2024 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICCM IceCure Medical Ltd. compare | −3.8× |
| CODX Co-Diagnostics, Inc. compare | −3.5× |
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| BJDX Bluejay Diagnostics, Inc. compare | n/m |
| DHAI DIH Holding US, Inc. compare | 0.1× |
| NXL Nexalin Technology, Inc. compare | 0.2× |
| IVF INVO Fertility, Inc compare | 0.2× |
| GCTK GlucoTrack, Inc. compare | 4.2× |
| ADGM Adagio Medical Holdings, Inc. | 30.6× |
| Medical Devices industry median | 2.8× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)